PreImplantation factor (PIF) detection in maternal circulation in early pregnancy correlates with live birth (bovine model) by Sivakumar Ramu et al.
Ramu et al. Reproductive Biology and Endocrinology 2013, 11:105
http://www.rbej.com/content/11/1/105RESEARCH Open AccessPreImplantation factor (PIF) detection in maternal
circulation in early pregnancy correlates with live
birth (bovine model)
Sivakumar Ramu1, Christopher Stamatkin1, Leo Timms2, Marshall Ruble2, Roumen G Roussev1,3
and Eytan R Barnea4,5*Abstract
Background: Early identification of viable pregnancy is paramount for successful reproduction. Detection of specific
signals from pre-implantation viable embryos in normal pregnancy circulation would indicate initiation of embryo-
maternal interaction and create a continuum to accurately reflect embryo/fetal well-being post-implantation. Viable
mammalian embryos secrete PreImplantation Factor (PIF), a biomarker which plays key, multi-targeted roles to
promote implantation, trophoblast invasion and modulate maternal innate and adaptive immunity toward acceptance.
Anti-PIF monoclonal antibody (mAb-based chemiluminescent ELISA) accurately detects PIF in singly cultured embryos
media and its increased levels correlate with embryo development up to the blastocyst stage. Herein reported that
PIF levels (ELISA) in early maternal serum correlate with pregnancy outcome.
Methods: Artificially inseminated (AI) blind-coded Angus cattle (N = 21-23) serum samples (day10,15 & 20 post-AI) with
known calf birth were blindly tested, using both non-pregnant heifers (N = 30) and steer serum as negative controls.
Assay properties and anti-PIF monoclonal antibody specificity were determined by examining linearity, spike and
recovery experiments and testing the antibody against 234 different circulating proteins by microarray. Endogenous
PIF was detected using <3 kDa filter separation followed by anti-PIF mAb-based affinity chromatography and confirmed
by ELISA and HPLC. PIF expression was established in placenta using anti-PIF mAb-based IHC.
Results: PIF detects viable pregnancy at day 10 post-AI with 91.3% sensitivity, reaching 100% by day 20 and correlating
with live calf birth. All non-pregnant samples were PIF negative. PIF level in pregnant samples was a stringent 3 + SD
higher as compared to heifers and steer sera. Assay is linear and spike and recovery data demonstrates lack of serum
interference. Anti-PIF mAb is specific and does not interact with circulating proteins. Anti-PIF based affinity purification
demonstrates that endogenous PIF is what ELISA detects. The early bovine placenta expresses PIF in the trophoblast
layer.
Conclusion: Data herein documents that PIF is a specific, reliable embryo-derived biomarker conveniently detectable
in early maternal circulation. PIF ELISA emerges as practical tool to detect viable early pregnancy from day 20 post-AI.
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In successful mammalian pregnancies, embryo-maternal
interaction develops immediately post-fertilization, even
before implantation occurs. This is evidenced by the de-
crease in circulating murine platelets observed within a
few hours post-fertilization [1,2,3].
Our focus in this context is to identify an embryo-
specific signal that conditions maternal response pre-
implantation and throughout viable pregnancy. This
embryo-maternal dialogue is paramount for both at initi-
ation and correlate with successful reproductive out-
come. We reported that a peptide, PreImplantation
Factor (PIF) (MVRIKPGSANKPSDD) is secreted by sin-
gly cultured, human, bovine and murine embryos [4-8].
Levels in embryo culture media could be detected using
a sensitive anti-PIF monoclonal antibody based mass
spectrometry and ELISA [6,8]. In singly cultured bovine
and murine embryos increased levels of PIF in the media
correlate with viable embryos development. In contrast,
PIF is absent in non-viable embryos [6]. Further, PIF is
up-taken by viable bovine embryos and when added to
singly cultured embryos it promotes their development
[6,7]. PIF plays an essential role in human pregnancy, as
it primes the endometrium for implantation, promotes
trophoblast invasion and regulates systemic immune re-
sponse [8-11]. In the context of recurrent pregnancy loss
(RPL) PIF has two demonstrated beneficial effects: acting
as a rescue factor to negate patients’ embryo-toxic serum
thereby preventing embryo demise and reducing sys-
temic NK cells cytoxicity [7,12]. We reported that PIF is
present in maternal circulation, and is expressed by the
human placenta and fetus [4,5,13-15]. Relevant to PIF’s
immune regulatory features, translational aspects to
treatment of non-pregnant autoimmune and transplant-
ation models were documented [16-19].
Our goal herein is to establish whether early detection
of PIF in maternal circulation correlates with embryo
viability and favorable reproductive outcome. PIF detec-
tion in maternal circulation, rather than in embryo cul-
ture media, would substantially broaden its potential use
as viability biomarker.
Bovine pregnancy provides a good model for examin-
ing PIF in this context for multiple reasons. For one, bo-
vine and human gestation length is similar. Further,
artificial insemination (AI) is conducive to documenting
the time of conception and collection of timed serum
sampling. Moreover, in the case of bovine pregnancy,
PIF testing may have significant utility in overcoming
current industry limitations in early viable pregnancy
diagnosis. Rectal palpation based diagnosis is made
only at >30 days post-AI. While ultrasound can be used
earlier (at >25 days), 10-15% of cases visualize a non-
viable embryonic sac [20,21]. Color doppler at day 20
diagnoses non pregnant cows with 74% accuracy [22].Progesterone levels decline prior to estrus [23,24]. Pla-
cental glycoproteins, and pregnancy proteins (60,
SBU-3 antigen, protein B and DG29) detect pregnancy
at ~30 days, however they may also be detected post-
partum [25-29]. Circulating nucleic acids can indicate
pregnancy at day 20 post AI with 75% accuracy and
InterferonTau induced neutrophil genes at day 21
[30-32]. Early cow pregnancy diagnosis is critical due
to the high loss rate at <16 days post-AI [33,34].
The objective of the present study was therefore to
apply the same PIF ELISA (previously used to identify
viable cultured bovine embryos) in order to detect PIF
in early bovine pregnancy serum and correlate its pres-
ence with successful calf birth. Equally significant, we
aimed to show lack of PIF indicates negative pregnancy
status. Serum samples were collected from Angus cattle
at 10–20 days post-AI, assayed for PIF, and followed
until viable birth, while non-pregnant heifers and steer
served as negative controls. Furthermore, anti-PIF anti-
body was used to determine presence of PIF in bovine
placenta as a possible source for post-implantation PIF
in circulation. In aggregate, the data generated herein es-
tablishes PIF as a valuable, embryo-derived signal whose
presence in early circulation indicates pregnancy status
earlier and more reliable than other methods.
Methods
Antibodies and reagents for the PIF ELISA
Biotin-conjugated mouse anti-PIF mAb, (BioIncept LLC,
proprietary) horseradish peroxidase (HRP)-conjugated strep-
tavidin (UltraAvidin-HRP), antigen-coating buffer and
tetramethylbenzidine (TMB) substrate were all obtained
from Leinco Technologies, Inc. (Saint Louis, MO). SEA
BLOCK blocking buffer was obtained from Thermo Scien-
tific (Waltham, MA). LumiGLO Peroxidase Chemilumines-
cent substrate was obtained from KPL, Inc. (Gaithersburg,
MD). Synthetic 15-Amino Acid PIF peptide (BioIncept
LLC, proprietary) and ovalbumin-conjugated PIF* were
produced by Bio-Synthesis Inc. (Lewisville, TX). The
sulfuric acid stop action solution and fish gelatin were
procured from Sigma-Aldrich Co. (St Louis, MO). The
LUMITRAC 600 flat-bottomed white polystyrene plates
used for the chemiluminescent assay were purchased
from Greiner Bio-One (Monroe, NC).
Bovine serum samples used to detect PIF
Serum samples were collected from 21–23 multiparous
dairy Angus beef cows following AI and generously pro-
vided by M. Ruble and L. Timms (Iowa State Univ. Ames,
IA). All samples were run blindly. These samples were
serially collected on days 10 (N = 23), 15 (N = 21) and 20
(N = 23) post-AI and the serum was separated and frozen
immediately. (Two of the day 15 samples were not avail-
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Figure 1 Standard curve used for competitive ELISA for
detecting PIF. The chemiluminescent standard curve was generated
by plotting the relative luminescence units (RLU) against the PIF
concentration, yielding a typical sigmoidal curve.
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cows were followed until calving. Once successful viable
delivery was accomplished, previously collected serum
samples were analyzed for PIF. In parallel, serum samples
from a group of 30 known non-pregnant heifers were col-
lected to use as non-pregnant controls. Steer sera were
also procured from Animal Technologies, Inc. (Tyler, TX)
for use as negative control and also to prepare standard
diluent. Before testing, samples were thawed, aliquoted
and coded. Serum samples underwent no more than one
freeze-thaw cycle during the storage period before thaw-
ing for analysis.
Chemiluminescent PIF ELISA
The chemiluminescent ELISA as validated in bovine em-
bryo culture media was previously reported [6]. (BioIncept,
LLC, Proprietary) Briefly, Ovalbumin-conjugated PIF was
diluted in 1X antigen-coating buffer (Leinco Technologies,
MO) to a concentration of 100 ng/mL. One hundred
microliters of this coating solution was added to LUMI-
TRAC polystyrene plates and incubated overnight at
room temperature. Plates were then washed with PBS-
T and then blocked with 300 μL/well of SEA BLOCK
blocking buffer for 2 hrs at 37°C. The plates were then
washed, air dried, and either used immediately or kept at
4°C in an airtight bag for up to 14 days. All serum samples
were run in triplicate. In addition a number of pregnant
serum samples were diluted neat, 1:2, 1:4 and 1:8 and
tested to determine the optimal dilution for PIF detection.
50 μL of PIF standard was prepared in steer serum
(0–1250 ng/ml) or test serum samples (diluted 1:8 in
PBS-T), added to appropriate wells and the location
marked using a plate layout. To this, 50 μL of biotin-
conjugated anti-PIF mAb (25 ng/mL in PBS-T) was
added to all wells, except the blank. Plates were then
incubated for 2 hrs at room temperature. Following in-
cubation, wells were washed four times with PBS-T and
then 100 μL of UltraAvidin-HRP, diluted to 50 ng/ml in
PBS-fish gelatin (1%) was added to each well and incu-
bated for 30 min at 37°C. Plates were washed four times
in an automated ELISA plate washer and 100 μL of
LumiGLO Chemiluminescent substrate was then added
to each well. After 5 min, the plates were read at
470 nm, with 0.5 sec integration time for each well in a
SpectraMax L microplate luminometer (Molecular De-
vices, Sunnyvale, CA). PIF ELISA was further optimized
using a checkerboard titration method. A representative
standard curve (Figure 1) shows that PIF level is accur-
ately detected at low analyte concentrations.
Determine PIF-ELISA linearity at various serum dilutions
and recovery following PIF spike
Since concentrations of PIF in a given sample may
greatly vary assay linearity determination at variousserum dilutions was carried out. Linearity is defined rela-
tive to the calculated amount of analyte based on the
standard curve, not relative to the raw absorbance mea-
surements. If the linearity is maintained over a wide range
of dilutions, then the assay method provides great flexibil-
ity to assay samples containing different PIF concentra-
tions. Three different concentrations, high, medium and
low levels of PIF were spiked in steer sera and diluted
two-fold serially. The experiment was repeated three times
and the mean percent recovery was calculated using
chemiluminescent ELISA, and quantified [6]. This docu-
mented that the PIF can be detected at a wide range of
concentrations and the serum used does not interfere with
PIF detection.Establish specificity of the anti-PIF mAb
The specificity and possible cross-reactivity of the anti-PIF
antibody were tested using a commercially available hu-
man protein array from Ray Biotech, Inc., Norcross, GA
(The RayBio Human Protein Array Product No. PAH-G1)
following manufacturer protocol by RayBiotech custom
service itself. Briefly, a total of 234 human recombinant or
native proteins were spotted in triplicate onto the surface
of a solid support (glass slide). A set of biotin-conjugated
proteins produced positive signals, which were then used
to identify their orientation and to compare the relative
expression levels among the different wells. The biotin-
labeled anti-PIF mAb, diluted 1:20,000 (the same dilution
used for the chemiluminescent PIF ELISA) (described
below) was then used to probe the array and bound pro-
teins were detected using streptavidin-conjugated Cy3
Fluor dye and <1% binding was considered non-specific
binding. This enabled determination of anti-PIF- mono-
clonal antibody’s specificity.
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isolation and testing by ELISA and HPLC
Serum from pregnant Angus cows, control heifers and
steers were concentrated using a Centricon 3000-dalton
cutoff filter (Millipore, Billerica, MA) following manufac-
turers protocol. This was based on consistent observation
[8] that all PIF activity is observed at the <3 KDa fraction.
The anti-PIF mAb was immobilized to AminoLink Plus
Coupling Resin (Pierce Biotechnology Inc., Rockford, IL)
to create an affinity column. The eluted <3 kDa fraction
was passed through the affinity column. Subsequently, an
aliquot of the purified samples were again tested by PIF
ELISA to confirm the validity of the affinity purification.
Purified samples were also run through HPLC (System
Gold HPLC, 24 Karat software, and 250 mm× 4.6 mm,
5 μm, 120 Å, C-18 Ultrasphere Column, Beckman Coulter,
Inc., Fullerton, CA). These experiments enabled HPLC
confirmation of the difference in retention times in the
affinity purified samples.
Evaluate PIF expression using anti-PIF-monoclonal
antibody-based immunohistochemistry (IHC) in the
placenta
Early pregnancy cow placental tissues were obtained
from a commercial abattoir (Animal Technologies, Inc.
Tyler, TX). Tissue was immediately frozen and sent on
dry ice to Zyagen Inc. San Diego Ca for IHC analysis.
Briefly, samples were dissected into 1 cm × 1 cm size
and fixed for 24 hrs in 10% neutral buffered formalin.
Next, samples were exposed to a 30% sucrose solution
overnight at 4°C and then placed in OCT solution VWR
(Westchester, PA) and frozen at −20°C. Samples were
then sectioned at a thickness of 7 μm and sections
mounted and fixed on glass slides.
For IHC, slides were treated with cold acetone for
5 min at −20°C (to enhance the permeability), air dried
for 15 min, washed for 5 min with 1X PBS, treated with
0.2% Triton X-100 in PBS for 10 min and washed with
1x PBS for 5 min. To block endogenous peroxidase ac-
tivity, slides were treated with 3% hydrogen peroxide in
methanol for 10 min and then washed with 1X PBS for
5 min.
The blocked sections were treated with 10% donkey
serum in PBS for 1 hr before decanting the solution.
The primary mouse Anti-PIF mAb was incubated for
2 hrs, at 1–200 μg/ml concentration. Biotinylated
Donkey Anti-mouse secondary antibody in PBS was in-
cubated for 1 hr followed by a wash for 5 min with 1X
PBS. The slides were then incubated with Avidin-
Peroxidase conjugate solution in PBS for 30 min. The
samples were incubated for 10 min in DAB substrate,
(Vector labs, catalog number SK-5100, Burlingame, CA)
with nickel (to increase the sensitivity). Finally, the sam-
ples were washed for 5 min each with 50%, 70%, 95%and 100% ethanol, followed by xylene for 5 min (two
changes) and then covered with a xylene-based mount-
ing medium with a coverslip for microscopic examin-
ation. As negative controls, sections were processed in
the absence of primary antibody, in the presence of non-
immune immunoglobin or in the presence of primary
antibody neutralized by an excess of peptide. This anti-
PIF antibody based detection enabled documentation of
PIF expression in the placenta.
Data analysis to establish PIF levels correlation with
pregnancy outcome
The chemiluminescent ELISA data was analyzed using
the SoftMax Pro software (Molecular Devices) following
a four-parameter logistic curve fitting, from which the
concentrations of unknown were derived and adjusted
for dilution.
A mean + 3SD (standard deviation) of the PIF concen-
trations (based on background absorbance values) in the
control heifer and steer samples was used as threshold.
The use of a +3SD provides a high 99.74%, stringent
evaluation of PIF presence in normal pregnancy. 2 tail
t test was used to analyze individual levels, where P < 0.05
was considered significant.
Results
PIF ELISA detects pregnancy in 100% at day20 post-AI
and PIF levels correlate with live birth
All negative controls test PIF negative
In this study we have only used bovine serum samples
which assured that all underwent synchronization defin-
ing the time of ovulation and insemination. Insemination
was performed only once and otherwise there was no
potential for later mating.
At day-10, 22/23 (95.6%) serum cow samples were
blindly diagnosed as pregnant using PIF ELISA (mean +
2SD) and subsequently calved. When using a more strin-
gent criteria, (mean +3SD) as a threshold cut-off for
non-pregnant cows only 21/23 (91.3%) were correctly
identified as pregnant. One cow tested by PIF as non-
pregnant at day 10; however by day 15 and 20 post-AI
she was detected to be pregnant by ELISA. At day 15
18/21 (85%) serum samples were correctly diagnosed as
pregnant. Remarkably, at day 20, 23/23 (100%) were de-
tected correctly. As negative controls, 30 heifers (never
inseminated or mated) and two steer samples were used.
All control samples tested negative as compared with
PIF positive samples (Figure 2). PIF concentrations in
pregnant samples serum range was (175–227) ng/ml at
day 10–20 post-AI and no significant changes in the
mean concentration were found at the tested days.
Background of PIF assay in non-pregnant animals is pre-
sented mean+/−SD (14+/−22) (Additional file 1: Figure S1).
The data illustrates the quartiles of the individual values
































Figure 2 PIF levels, day 10- post AI vs. control and day-20 post AI vs. control. PIF levels were determined by ELISA at different days after AI
in cows with documented calf delivery. Levels were compared with non-pregnant never inseminated animal. A stringent +3SD threshold
(99.74%) was used vs controls. As expected, non-pregnant control PIF levels overlap with a small number of day-10 post-AI subjects, whereas by
day-20, there is clear stratification.
Table 1 PIF detection by ELISA
Dilution factor
(DF)
Observed (ng/ml) Expected ng/ml Recovery
%X DF (neat value)





















ELISA is linear at different dilutions and spiked PIF recovery is >90%. Observed
values were assessed relative to the assay standard curve produced by a PIF
standard prepared in the steer sera.
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trations increased, and the lowest levels at day 20 were
much higher than that observed at day 10. Thus PIF detection
in early pregnancy circulation correlates with live calf birth.
PIF detection is linear at different dilutions and at
different spiked PIF concentrations: serum does not
interfere with PIF detection
One important element in assay performance is specific
detection of low analyte concentration significantly higher
than the assay background. This was accomplished using
the +3SD as threshold. Using different dilutions of sera
with spiked PIF documented accurate detection at neat
and up to 1:8 dilution of the sample (Table 1).
To rule out any serum interference with PIF, “spike and
recovery” experiments were performed, at low, mid and
high concentration (Table 1). Data showed that recovery of
PIF was >90% in all concentration ranges while the blank
value was zero. This indicated that serum does not interfere
with PIF detection. Having previously shown the specificity
of the PIF ELISA in embryo culture media, we now show
that PIF ELISA in serum is equally reliable as well.
Anti-PIF antibody is highly specific: does not interact with
circulating proteins
In contrast to embryo culture media where PIF was accu-
rately detected by ELISA and correlated with pregnancy
outcome, in maternal circulation we face a large number of
proteins that could be interacting with the antibody in sera
and thus interfere with the assay. To confirm the anti-PIF
antibody specificity, an array of 234 circulating proteins to
determine cross reactivity with the monoclonal antibody
was used. The antibody did not interact with 232/234
99.1% of evaluable proteins. (Figure 3) Weak reactivity was
detected with [Chemokine (C-C motif) ligand 15 (CCL15)
(macrophage-inflammatory protein (MIP 1δ)] and tissue in-
hibitor of metalloproteinase 3 (TIMP3). Spiking protein
(MIP 1δ) into sera samples did not affect ELISA sensitivity
(data not shown), while the (TIMP3) interaction with anti-PIF mAb on the array was low, six fold lower than (MIP
1δ), reflecting a non-specific interaction-which actually is
lower than the background. The individual antibody specifi-
city data is presented in Additional file 2: Table S1. Thus,
we demonstrate that anti-PIF mAb is highly specific.
Accurate detection of endogenous PIF in pregnant sera
by ELISA after anti-PIF mAb based affinity chromato-
graphic separation: HPLC confirmation
To determine whether the antibody used is specific and ac-
curate to detect endogenous PIF in serum samples, we have
performed multistep PIF isolation and confirmed by ELISA.
Five AI-bred pregnant cows samples were pooled and
passed through an <3 kDa filter followed by an anti-PIF
mAb based affinity column. The collected elute of native
Figure 3 HPLC profile of PIF in pregnant sera. The retention time of PIF is shown in sera from (A) a pregnant cow, but not (B) in steer sera.
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detection. In contrast, the heifer and steer samples pro-
cessed in the same manner had no PIF activity.
The detection of endogenous PIF was also examined by
using <3 kDa filter and anti-PIF affinity chromatography
followed by HPLC. The collected samples were injected
into reversed phase HPLC (Figure 4). The pregnant sam-
ple profile showed a shorter retention time as compared
with the steer samples. Overall such data indicates thatFigure 4 The PIF mAb is specific. Biotin-labeled mouse, anti-PIF mAb wa
PIF mAb did not react with any of the proteins except two, (left side) MIP-1
compared with controls. The biotin labeled and spotted proteins act as positiPIF ELISA detects endogenous PIF similarly to that
present in embryo culture media.
PIF source in post-implantation gestation is found also in
the placenta
Once we found that PIF is detected in maternal circula-
tion, it was of interest to explore whether the placenta
provides an additional source of PIF after implantation
occurs. The placental sample analyzed was from an earlys screened against 243 circulating human proteins using an array.
Delta and (right side) TIMP3, circled by arrow, which were <1% as
ve control (highlighted in two rectangles on either side of the array).
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endogenous PIF was found to be expressed mostly in the
trophoblastic layer. Since a sandwich ELISA method was
used (as opposed to direct detection), this required a ra-
ther high antibody concentration to be used for staining.
The effect was dose dependent.- the most intense staining
was noted at the highest antibody concentration. The use
of nickel metal enabled significant enhancement of the
PIF staining (Additional file 3: Figure S2). In contrast, the
same samples tested against the mouse isotype antibody
(control) were negative reflecting detection specificity.
Endogenous circulating PIF is likely secreted by the placenta
thus allowing its measurement in maternal circulation.
Discussion
We have previously established that PIF is an essential
embryo-derived signal present in singly cultured viable
post-IVF embryos culture media (bovine) [6]. Herein, we
provide evidence in the same species using a stringent
threshold, that PIF presence in maternal serum corre-
lates with pregnancy outcome and predicts whether
pregnancy will be successful. We also provide equally
significant utility, confirming a lack of pregnancy in
serum found to be PIF-negative (less than threshold
level). Using the convenient bovine model, PIF ELISA at
10 days post-AI predicts live birth with >91% accuracy
and this reaches 100% by day 20 post AI. This provides
strong evidence that embryo-derived PIF signaling pres-
ence in maternal circulation is an indicator of embryonic
health and a potent predictor of pregnancy outcome.
We furthermore report that while prior to implantation
PIF is secreted by the embryo, the placenta adds a major
source of post-implantation PIF, enabling serum-based
detection. PIF is hereby established as an accurate bio-
marker of early cattle gestation.
A number of steps were carried out to establish the
PIF ELISA validity. Assay linearity and spike and re-
covery experiments confirmed assay precision in ligand
detection. The multistep PIF isolation from pregnant
serum documented detection of endogenous PIF by
ELISA. The generated HPLC profile further confirmed
differences between pregnant and non-pregnant sam-
ples. Anti-PIF-antibody testing against large number of
circulating proteins documented target specificity. It
has to be noted that specificity was directed against
human proteins; therefore, interaction of anti-PIF anti-
body with bovine specific proteins cannot entirely be
excluded. However, since in spike and recovery experi-
ments PIF added to the serum was mostly recovered, if
there is interference it is only minor and should not
impair the assay performance. These overall data sup-
port the view that the ELISA used to detect PIF in bo-
vine embryo culture media identifies a highly similar
biomarker in maternal circulation [6].Our study aimed to define an assay’s sensitivity and spe-
cificity at the earliest stages of gestation therefore blinded
synchronized mating enabled exact timing of sample col-
lection. The identical cow population and same number
of cows serially tested at day 10 and 20 post-AI allowed
evaluating accurately sequentially calf delivery rates by di-
rect comparison between the two time points.
Also, since PIF ELISA was shown highly effective to
diagnose controls as non-pregnant (heifers and steer)
this assay could be used to document failed AI even be-
fore cows would have already returned to estrus. Further
studies should examine whether PIF ELISA can also pre-
dict pregnancy loss in cows since PIF was shown instru-
mental to predict and prevent RPL based pathologies in
women [7,12].
Presence of PIF in cow placenta confirmed our earlier
data which demonstrated the same expression in human
placenta and fetus [5]. The earlier data was generated by
using affinity-purified polyclonal antibody while in this
study the monoclonal antibody was used for staining.
This further confirms expression of PIF in the placenta
and helps explain the origin of circulating peptide later
in pregnancy.
The PIF ELISA is a rapid and simple-to perform serum
assay with high sensitivity and specificity and which cur-
rently takes only ~3 h to perform. The built-in software
in the plate reader used in this study allows for immedi-
ate and precise data output. Therefore, adaptation to
cow-side diagnostics is highly feasible once confirmed in
larger studies.
Pertinent to PIF biomarker in cows at 10 day post-
fertilization, the embryo is free and not attached to the
uterus. Therefore, the PIF signal identified in maternal
circulation is confirmed as purely embryonic. By day 20
the embryo has reached the uterine cavity. However only
by day 33 attachment to the uterus takes place and by
day 42 implantation is firmly established [35].
The study is limited since it was retrospective in na-
ture and two samples at day 15 were not available for
analysis. Also larger numbers of animals are required in
order to document PIF effectiveness as a clinical tool.
However, the retrospective approach was deliberate
since, in absence of another marker that can detect very
early pregnancy, we serially tested only those animals
which successfully ended with a live birth. This was
compared to data with established non-pregnant con-
trols. Further strength of the study is assay validation
analyzing antibody characteristics. Finally detection of PIF
in cow placenta provides evidence that post-implantation
is a source of circulating PIF.
Conclusions
PIF ELISA accurately documents pregnancy outcome
shortly post-AI, by day 20, it correlates 100% with
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at 100% with a non-pregnant status. The placenta serves
as an important added source of PIF post-implantation,
enabling detection in maternal serum. The observations
herein have wider translational implications for PIF as a
pregnancy diagnostic beyond bovine. Since bovine and
human pregnancy length is highly similar (250–280 days),
lessons learned from one species could be valuable for
the other. We herein strengthen PIF’s premise that
shortly post-conception, pregnancy outcome status can
be defined and PIF presence or absence is a critical
element in this equation correlating with gestation suc-
cess or failure. Our ongoing multicenter human clinical
trials address PIF detection and correlation of its levels
with pregnancy outcome both in embryo culture media
and serum (Clinical trials.gov).Additional files
Additional file 1: Figure S1. PIF levels expressed as quartiles.
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Additional file 2: Table S1. Testing of anti-PIF-monoclonal antibody
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than the control. All other values were lower than the positive control.
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